Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cynata Therapeutics (CYP) receives approval from the US Food and Drug Administration (FDA) to commence its Phase 2 clinical trial of CYP-001
  • CYP-001 is the company’s lead product aimed at treating patients with acute graft versus host disease (aGvHD)
  • The planned Phase 2 aGvHD trial will be the company’s first clinical trial conducted in the US, which is the largest healthcare market worldwide
  • Enrolment for the trial is expected to begin later this year, with results of the primary evaluation anticipated in early 2024
  • Cynata Therapeutics shares are up 11.1 per cent, trading at 40 cents as of 10:14 am AEST

Cynata Therapeutics (CYP) has had its investigational new drug (IND) application approved by the US Food and Drug Administration (FDA), allowing the Phase 2 clinical trial of CYP-001.

CYP-001 is Cynata’s lead product aimed at treating patients with acute graft versus host disease (aGvHD).

Chief Operating Officer Dr Kilian Kelly said the approval represents “a hugely important milestone in the development of CYP001 and our Cymerus platform.”

“Clearance of our IND application confirms that the FDA is satisfied with both the clinical and preclinical data as well as the manufacturing and quality control data on our product that we submitted in support of this application,” he said.

Dr Kelly also said the company previously completed several positive interactions with the FDA, as well as securing orphan drug designation for CYP-001 in 2018.

The planned Phase 2 aGvHD trial will be the company’s first clinical trial conducted in the US, which is the largest healthcare market worldwide.

The clinical trial will seek to recruit approximately 60 patients with high risk aGvHD,
at clinical centres in a number of countries, including the US and Australia.

The primary objective of the trial is to assess efficacy of CYP-001 in subjects with high risk aGvHD by overall response rate (ORR) at Day 28.

Participants will be randomised to receive either CYP-001 or placebo, in addition to corticosteroids.

The trial is expected to commence enrolment later this year, with results of the
primary evaluation expected in early 2024.

Cynata Therapeutics shares were up 11.1 per cent, trading at 40 cents as of 10:14 am AEST.

CYP by the numbers
More From The Market Herald

" Dimerix’s (ASX:DXB) DMX-700 study shows significant 80pc reduction in lung injury

Dimerix (ASX:DXB) has released its pipeline program DMX-700 study results which indicated a significant 80 per…

" Tesoro Gold (ASX:TSO) confirms El Zorro as a new Chilean Gold District

Tesoro Gold (ASX:TSO) has confirmed its El Zorro project as a new Chilean Intrusive Related Gold…
OncoSil Medical (ASX:OSL) - Managing Director & CEO, Nigel Lange

" Bupa UK becomes first insurance company to reimburse for OncoSil Medical’s (ASX:OSL) namesake device

Bupa UK Insurance has become the first health insurance company to provide reimbursement for OncoSil Medical's…

" Patrys (ASX:PAB) completes second engineering run for PAT-DX1

Biotech junior Patrys (ASX:PAB) has completed a second engineering run for its PAT-DX1 cancer antibody candidate…